The Hong Kong Securities and Futures Commission directed the Stock Exchange of Hong Kong to suspend trading in Cloudbreak Pharma Inc. shares from 9 a.m. over serious concerns that the company’s initial public offering may have been rigged to create an artificial impression of demand. The suspension will remain in place while the commission investigates the matter. The regulator considers the action necessary to maintain an orderly and fair market and protect investors. Cloudbreak has been listed on the exchange’s Main Board since July 3, 2025.